Complementary
Scientist Turned Entrepreneur to Tackle Diabetes: Novel Therapy in the Making
Received Date:July 01, 2019; Published Date:July 02, 2019
Abstract
The following article discusses the current status of a novel tool, ET-traps, which is an Fc fusion protein that may become a potential therapeutic for use in diabetes, as well as various other diseases associated with pathologically elevated endothelin-1 levels. The ET-traps have a very high and fast association to their target (endothelin-1) and a very slow dissociation once bound to their target.
Dr Arjun Jain, Founder and Managing Director of ET-traps Limited, reminisced about his journey from scientist to entrepreneur.
Keywords: Endothelin-1; ET-traps; Diabetes; Cardiovascular diseases; Neurodegenerative disorders; Cancers
-
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
